Replimune Group Inc (REPL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Replimune Group Inc (REPL) has a cash flow conversion efficiency ratio of -0.313x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.95 Million) by net assets ($210.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See REPL days of operational coverage to measure how many days the company can operate on defensive assets alone.
Replimune Group Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Replimune Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Replimune Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Replimune Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ponsse Oyj 1
HE:PON1V
|
-0.035x |
|
Kornit Digital Ltd
NASDAQ:KRNT
|
0.009x |
|
Hindustan Foods Limited
NSE:HNDFDS
|
0.091x |
|
Doctorglasses Chain Co Ltd
SHE:300622
|
0.160x |
|
Geron Corporation
NASDAQ:GERN
|
-0.275x |
|
Anhui Ronds Science & Technology Inc Co
SHG:688768
|
-0.637x |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
-0.002x |
|
Minerva S.A
SA:BEEF3
|
-0.175x |
Annual Cash Flow Conversion Efficiency for Replimune Group Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Replimune Group Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Replimune Group Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $415.84 Million | $-192.25 Million | -0.462x | +6.65% |
| 2024-03-31 | $374.51 Million | $-185.47 Million | -0.495x | -114.76% |
| 2023-03-31 | $555.29 Million | $-128.05 Million | -0.231x | -15.39% |
| 2022-03-31 | $411.23 Million | $-82.18 Million | -0.200x | -62.35% |
| 2021-03-31 | $498.73 Million | $-61.39 Million | -0.123x | +62.65% |
| 2020-03-31 | $183.72 Million | $-60.55 Million | -0.330x | -79.04% |
| 2019-03-31 | $137.86 Million | $-25.38 Million | -0.184x | -132.27% |
| 2018-03-31 | $-28.07 Million | $-16.01 Million | 0.571x | -7.17% |
| 2017-03-31 | $-11.52 Million | $-7.08 Million | 0.615x | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more